SCHOTT Pharma: Christian Mias to succeed Andreas Reisse as CEO of SCHOTT Pharma

• Andreas Reisse to retire as CEO of SCHOTT Pharma as planned
• Christian Mias, Executive Vice President of SCHOTT’s Electronic Packaging Business Unit, appointed as new CEO of SCHOTT Pharma effective May 1^st, 2026
• Seamless leadership transition ensured

The Supervisory Board of SCHOTT Pharma Management AG has appointed Christian Mias as CEO of SCHOTT Pharma. He will take over from Andreas Reisse, who will retire as planned in April 2026. Reisse will actively support a seamless leadership transition over the coming months to ensure continuity and stability for the company and the entire team.

Christian Mias, born in Iserlohn in 1974, will succeed Andreas Reisse starting May 1^st. As an industrial engineer with a doctoral degree, he looks back on more than 20 years of management experience, including over 18 years within the SCHOTT group. Before joining SCHOTT, he started his career as Commercial Project Manager at Siemens AG. Christian Mias gained significant experience in the pharmaceutical industry when joining SCHOTT Tubing, which produces intermediate products for the pharma sector, including SCHOTT Pharma. Throughout his career at SCHOTT, Christian has held leadership positions across various business units and continents, including roles as Managing Director in Brazil and Chief Operating Officer in the United States. In such roles, he successfully drove profitable growth by optimizing processes, improving productivity, and increasing earnings quality. Since 2016, he has served as Vice President, and since 2018 as Executive Vice President, currently heading the Business Unit Electronic Packing. Across his executive positions, Christian combined strategic foresight with operational discipline to drive the organizations toward consistent growth and strong financial performance.

Peter Goldschmidt, Chairman of the Supervisory Board of SCHOTT Pharma AG & Co. KGaA, said: “We are delighted to welcome Christian Mias as the new CEO of SCHOTT Pharma. His proven success within the SCHOTT Group, combined with strategic expertise and strong execution -demonstrated through integrative, performance-oriented, and participative leadership – makes him an excellent fit to lead SCHOTT Pharma into its next phase of profitable growth.

We are confident that Christian, together with Reinhard Mayer (CFO), will continue to drive profitable growth and further strengthen SCHOTT Pharma’s position as a global leader in pharmaceutical packaging and delivery systems.”

Commenting on his appointment, Christian Mias said: “I am honored to join SCHOTT Pharma at such an exciting time in the company’s journey. SCHOTT Pharma has built an exceptional reputation for innovation, quality, and reliability in the pharmaceutical industry. I look forward to working with the excellent team at SCHOTT Pharma to build upon this strong foundation and drive continued growth while advancing our mission to improve global healthcare. I would also like to thank Andreas Reisse for his outstanding leadership and dedication over the years. His vision and commitment have been instrumental in shaping SCHOTT Pharma’s success. I am looking forward to working together with Reinhard Mayer (CFO) on shaping the future of SCHOTT Pharma.”

Andreas Reisse has been with the SCHOTT Group since 1987 and has led the “Pharmaceutical Systems” division since 2010, which has been listed on the Frankfurt Stock Exchange as SCHOTT Pharma AG & Co. KGaA since 2023. He is now retiring upon reaching the statutory age limit for members of the Executive Board.

“Andreas Reisse has played an indispensable role in developing SCHOTT Pharma into one of the world’s leading companies in pharmaceutical containment solutions and delivery systems. Under his leadership, the company has achieved remarkable growth, delivered industry-leading innovations, and successfully transitioned to a publicly listed company. We thank him for his exceptional contributions and wish him all the best for his well-deserved retirement,” said Peter Goldschmidt.

Andreas Reisse commented: “It has been a privilege to spend so many years at SCHOTT Pharma and within the SCHOTT Group. I am very grateful for the collaboration and trust I have had with all stakeholders and the Supervisory Board. Together with a dedicated management team, we have established SCHOTT Pharma as a key partner in the pharmaceutical industry and achieved significant milestones, such as the successful IPO. As I prepare for retirement, I am confident that the company is well positioned for continued success and innovation. SCHOTT Pharma will be in excellent hands with Christian Mias, whom I have known and appreciated for almost two decades.”

For further news about SCHOTT Pharma, please visit our Media Center.

About SCHOTT Pharma

Human health matters. That is why SCHOTT Pharma designs solutions grounded in science to ensure that medications are safe and easy to use for people around the world. Every minute, more than 25,000 people receive an injection packed in a SCHOTT Pharma product. The portfolio comprises drug containment solutions and delivery systems for injectable drugs ranging from prefillable glass and polymer syringes to cartridges, vials, and ampoules. Every day, a team of around 4,700 people from over 60 nations works at SCHOTT Pharma to contribute to global healthcare. The company is represented in all main pharmaceutical hubs with 17 manufacturing sites in Europe, North and South America, and Asia. With over 1,000 patents and technologies developed in-house and a state-of-the-art R&D center in Switzerland, the company is focused on developing innovations for the future. SCHOTT Pharma AG & Co. KGaA is headquartered in Mainz, Germany and listed on the Frankfurt Stock Exchange as part of the SDAX. It is majority owned by SCHOTT AG, which is owned by the Carl Zeiss Foundation. In light of this spirit, SCHOTT Pharma is committed to sustainable development for society and the environment. Currently, SCHOTT Pharma has over 1,800 customers including the top 30 leading pharma manufacturers for injectable drugs and generated revenue of EUR 957 million in the fiscal year 2024. Further information at www.schott-pharma.com.   

Contact

Katrin Schreyer

Corporate Communications

Tel.: +49 (0) 6131 66-4932

E-Mail: katrin.schreyer@schott.com 

Lea Kaiser

Media Relations

Tel.: +49 (0) 6131 66-2422

E-Mail: lea.kaiser@schott.com 

Tobias Erfurth

Head of Investor Relations

E-Mail: Tobias.Erfurth@schott.com

Jasko Terzic, CFA

Senior Manager Investor Relations

E-Mail: Jasko.Terzic@schott.com

Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ: EVO) today announced its business update for 9M 2025, illustrating the ongoing systematic execution of its strategy. In the D&PD segment, the market for early drug discovery services remained soft, while strategic partnerships are on track and Evotec records strong progress in its partnered asset pipeline. JEB continues its strong momentum and reports further accelerating growth in the non-Sandoz / non-DoD business.

After the end of the period, Evotec signed a > US$ 650 m landmark transaction with Sandoz AG (SIX:SDZ/OTCQX:SDZNY) on 04 November. According to the terms of the agreement, Sandoz will acquire 100% of Just – Evotec Biologics EU in Toulouse plus an indefinite technology license to Evotec’s continuous manufacturing platform technology for a payment of approximately US$ 350 m in cash. The agreement includes additional license fees and development revenues including success-based milestones, adding up to more than US$ 300 m in the coming years, replacing existing contractual commitments. In the future, Evotec expects to benefit from royalties on a portfolio of up to ten biosimilars in technical and early development, targeting a net-originator sales market of more than US$ 90 bn.

Dr Christian Wojczewski, Chief Executive Officer of Evotec:

“Evotec remains firmly on track in delivering against its strategic objectives, demonstrating strong execution for future sustainable and profitable growth. Despite a continued softness in the early drug discovery market, we are seeing first signals of improvement in our base business in D&PD. With 11% revenue growth year-over-year, JEB is not only enjoying high demand but also delivering strong results above our expectations. The agreement with Sandoz enables us to sharpen our focus on JEB’s capabilities as a scalable technology provider with an asset-lighter model. The transaction is a testament for our world class continuous manufacturing technology. A core element of our new strategy is to sharpen our offering and reduce complexity while progress in our strategic partnerships continues to build momentum.“
 

Continuing challenges for D&PD; JEB building strong momentum

• Group revenues decrease by (7.1)% to € 535.1 m (9M 2024: € 575.7 m)
• Total D&PD revenues decrease by (12.3)% to € 392.1 m (9M 2024: € 447.1 m), due to soft demand in the early drug discovery service market; quotations are growing in number and value, negative change orders are declining
• JEB revenues increase by 11.3% to € 143.4 m (9M 2024: € 129.3 m), driven by continued strong non-Sandoz / non-Department of Defense (“DoD”) business growth of 105% year over year
• Adjusted Group EBITDA totaled € (16.9) m (9M 2024: € (6.0) m) driven by continued underutilization and a high fixed cost base in the D&PD segment as well as costs related to the ramp-up of the JEB Toulouse facility
• Cost out initiatives ahead of plan, expected to result in a total cost reduction of more than € 60 m in 2025 (2x initial target)
   

Driving growth through strategic priorities

• Significant progress in the strategic protein degradation collaboration with Bristol Myers Squibb (“BMS”) resulted in performance- and program-based payments amounting to US$ 75 m the first half of the year
• In the second quarter, Evotec reported key advancements in its neuroscience collaboration with BMS, resulting in a US$ 20 m research payment to the company
• Two partnered assets entered Phase II clinical trials
   

Events after Period-End

• In a landmark industry transaction, Evotec signs agreement with Sandoz, resulting in payments of potentially over US$ 650 m plus royalties on a portfolio of up to 10 biosimilar molecules
• Progress in the strategic preclinical neuroscience partnership with BMS resulted in a payment of US$25m to support the continued progression of joint programs
• Investigational New Drug (“IND”) submission by partner Dewpoint Therapeutics for novel oncology therapy marks culmination of the partnership, advancing a de novo development candidate from discovery through IND-enabling studies
• Evotec’s collaboration with Esperion leads to the nomination of a preclinical development candidate for the treatment of Primary Sclerosing Cholangitis, a chronic, progressive disease-causing inflammation and sclerosis of the bile ducts leading over time to liver cell damage and can result in fibrosis, cirrhosis, and eventually liver failure
   

Guidance for full-year 2025 confirmed

• Group revenues expected in the range of € 760 – 800 m (2024: € 797.0 m)
• R&D expenditures are expected in a range of € 40 – 50 m (2024: € 50.9 m)
• Adjusted Group EBITDA is expected to reach € 30 – 50 m (2024: € 22.6 m)
   

Outlook 2028

• Group revenues CAGR _2024-2028 targeted to be in a range of 8 – 12%
• Adjusted EBITDA margin 2028 expected to be above 20%

More detailed information and financial tables are available in the interim statement for the first nine months 2025 published on the Evotec website under the following link: https://www.evotec.com/en/investor-relations/financial-publications

Webcast/Conference Call

The Company is going to hold a conference call to discuss the results as well as provide an update on its performance. The conference call will be held in English.

Webcast details

Date:  Wednesday, 05 November 2025

Time:  2.00 pm CET (01.00 pm GMT, 08.00 am EST)

To join the audio webcast and to access the presentation slides, please register via this link.

The on-demand version of the webcast will be available on our website: Financial Publications – Evotec.

Conference call details

To join via phone, please pre-register via this link. You will then receive a confirmation email with dedicated dial-in details such as telephone number, access code and PIN to access the call.

A simultaneous slide presentation for participants dialling in via phone is available

About Evotec SE
Evotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure — faster, smarter, and with greater precision.

Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling.

With flexible partnering models tailored to our customers’ needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility.

Through Just – Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability.

With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology.

Evotec’s global team of more than 4,800 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. Learn more at www.evotec.com and follow us on LinkedIn and X/Twitter @Evotec.

Forward-looking statements
This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec’s securities. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec’s expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

For further information, please contact:

Investor Relations

Volker Braun
EVP Head of Global Investor Relations & ESG
Volker.Braun@evotec.com

Hamburg, Germany, 04 November 2025:
 

Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ: EVO), a life science company that is pioneering the future of drug discovery and development, today announced the successful signing of the sale of the Just – Evotec Biologics Toulouse site to Sandoz AG (SIX: SDZ / OTCQX: SDZNY), a global leader in generic and biosimilar medicines.

Under the landmark transaction, Sandoz will acquire 100% of Just – Evotec Biologics EU plus an indefinite technology license to Evotec’s continuous manufacturing platform technology for a payment of approximately US$ 350 m in cash. The agreement includes additional license fees and development revenues including success-based milestones, adding up to more than US$ 300 m in the coming years. In the future, Evotec expects to benefit from royalties on a portfolio of up to ten biosimilars in technical and early development targeting a net originator sales market of more than US$ 90 bn.

With this acquisition, Sandoz will gain access to Evotec’s proprietary platform for integrated development and advanced continuous manufacturing of biologics via an indefinite license.

The contract signature follows the announcement in July of a non-binding term-sheet agreement on 30 July 2025. Both parties aim to close the transaction in Q4 2025 subject to meeting closing conditions including foreign direct investment (FDI) clearance by the French authorities. The transaction will have a significant positive impact on Evotec’s revenue mix, profit margins, and capital efficiency immediately after closing.

Dr Christian Wojczewski, Chief Executive Officer of Evotec, said:

“This is a transformative milestone for Evotec as we further leverage Just – Evotec Biologics’ capabilities and position the company as a scalable technology provider. With our unique offering, we are expanding the scope of addressable partners and shaping a new segment in the biologics manufacturing market in a very capital efficient way. Additionally, with this transaction, Evotec is delivering on its asset lighter strategy, sharpening its focus on its core strengths, and is well on track for sustainable and profitable growth.”

Dr Linda Zuckerman, EVP and Global Head of Just – Evotec Biologics, said:

“Sandoz’s acquisition of Just – Evotec Biologics’ Toulouse site is a powerful endorsement of our pioneering J.POD platform and its potential to revolutionize biologics manufacturing. This strategic transaction empowers Sandoz to leverage our advanced perfusion-based continuous manufacturing technology, progressing our shared mission to expand global access to affordable, high-quality biosimilars. We are proud to see our innovation continue to have a transformative impact for patients around the world.”

After closing of the transaction, Evotec will continue to serve our customers in the U.S. and Europe with capacity for molecular design, upstream, downstream, analytical and formulation development as well as First-In-Human to commercial biologics GMP manufacturing.

Evotec confirms guidance for full-year 2025 and its Outlook 2028

For the current fiscal year, the Company expects revenues in the range of € 760 – 800 m (2024: € 797.0 m);

R&D expenditures are expected in a range of € 40 – 50 m (2024: € 50.8 m);

Adjusted EBITDA¹ is expected to reach € 30 – 50 m (2024: € 22.6 m).

Outlook 2028 remains unchanged with a targeted Group revenue CAGR_2024-2028 in a range of 8 – 12% and an expected adj. EBITDA margin above 20% by 2028.

^{1 Excluding potential costs related to the transformation program in 2025
CAGR: Compound annual growth rate}

About Evotec SE
Evotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure — faster, smarter, and with greater precision.

Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling.

With flexible partnering models tailored to our customers’ needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility.

Through Just – Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability.

With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology.

Evotec’s global team of more than 4,800 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. For additional information please go to www.evotec.com and follow us on X/Twitter @Evotec and LinkedIn.

Forward-looking statements
This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec’s securities. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec’s expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

For further information, please contact:

Investor Relations

Volker Braun
EVP Head of Global Investor Relations & ESG
volker.braun@evotec.com

• Group operating result amounts to EUR 48.9 million (9M 2024: EUR 34.5 million)
• Consolidated group sales amounts to EUR 586.9 million (9M 2024: EUR 558.2 million)
• Overall capacity utilisation stable at 86.8%

For further information:

MEDICLIN Aktiengesellschaft
Okenstraße 27
77652 Offenburg

Investor Relations
Ender Gülcan
Tel.: +49781/488-326
ender.guelcan@mediclin.de

www.mediclin.de

About MEDICLIN Aktiengesellschaft (Ticker: MED; WKN: 659 510)

MEDICLIN ─ a company of the Asklepios Group

Mallia Aesthetics Launches 8T3 Essentials Hair Serum and
8T3 Essentials Lash & Brow Serum

• Mallia launches new web shop with its 8T3 Essentials Line
• 8T3 serums are the first products for stimulating hair growth based on the immunomodulatory mode of action of sCD83
• 8T3 Essentials Hair Serum and 8T3 Essentials Lash & Brow Serum can now be ordered via Mallia’s online shop 8T3.com

Erlangen, Germany, November 04, 2025 – Mallia Aesthetics GmbH, a company focusing on the development and commercialization of cosmetic products to stimulate hair growth, today announced the official market launch of its innovative 8T3 Essentials Hair Serum and 8T3 Essentials Lash & Brow Serum. 8T3 Essentials Serums will be available exclusively via Mallia’s online shop 8T3.com for customers in the EU.

All products in the 8T3 line are hormone-free, dermatologically tested, certified microbiome-friendly, and with excellent tolerability on sensitive skin.

8T3 Essentials Hair Serum supports and enhances hair density and thickness. The product is designed for biweekly application to the scalp using single-dose, preservative-free vials. It will be available in 6-month boxes.

8T3 Essentials Lash & Brow Serum promotes growth and thickness of eyelashes and eyebrows. The serum is sold in vials with an integrated applicator brush and should be used daily for the best results.

The 8T3 Essentials product line is built on the active ingredient MAL-838, a proprietary derivative of the human soluble CD83 protein. Mallia co-founder Prof. Dr. Alexander Steinkasserer and his team have shown that sCD83 possesses immunomodulatory properties, which can stimulate wound healing and new hair growth, and have published these results in a peer-reviewed journal.¹

Dr. Anne Asmuß, Managing Director of Mallia Aesthetics, said: “We are excited to see years of dedicated research and meticulous planning come to fruition as we today introduce our science-driven cosmetics to the market. For the first time, consumers will be able to benefit directly from the mode of action of an sCD83 derivative in the form of hormone-free, scientifically grounded formulations. With 8T3, we offer products that are convenient, safe, and designed for visible results.”

About sCD83

Soluble CD83 (sCD83) is an immunomodulatory protein that is currently being developed for the topical treatment of hair loss (MAL‑856) and stimulation of hair growth (MAL‑838). The soluble CD83 protein was first identified in 2001 by Mallia co-founder Prof. Steinkasserer. It has anti-inflammatory properties via the induction of resolution of inflammation, which promotes wound healing and induces new hair growth.¹ In addition, sCD83 has been shown to activate regulatory T cells (Tregs)², which interact directly with hair follicles and can activate them.³ Furthermore, sCD83 inhibits cell death of hair follicles and directly activates follicular stem cells, as well as keratin production, thereby stimulating new hair growth. This multimodal mode of action distinguishes sCD83 from other topically applied hair growth agents.

Topically applied, sCD83 can directly reach the hair follicles but does not penetrate through the skin and thus does not enter the bloodstream. The effect is localized, which is a major advantage over systemic treatment options, which can cause severe side effects.

About hair loss

Hormone-related hair loss in men and women (androgenetic alopecia, or AGA) is the most common form of hair loss. Worldwide, more than 70% of men and 50% of women post menopause are affected by androgenetic alopecia. Another 147 million people suffer from immune-related, circular hair loss (alopecia areata, or AA^4,5).

Androgenetic alopecia usually progresses gradually and is due to genetic and hormonal factors. In men, it often leads to a receding hairline and baldness on the top of the head, while in women it causes thinning hair in the parting area. Alopecia areata causes circular hair loss on the scalp, face or other parts of the body. It occurs when the immune system erroneously attacks hair follicles, leading to immune-mediated hair loss.

About Mallia

Mallia Innovations GmbH, based in Erlangen, Germany, is the holding company strategically driving the proprietary development and commercialization of biopharmaceutical therapies and cosmetic applications of the immunomodulatory sCD83 protein, targeting hair growth, hair loss and other dermatological indications, including wound healing.

Mallia Therapeutics GmbH focuses on the clinical development of novel therapies for patients suffering from androgenetic alopecia or alopecia areata, among other conditions. MAL-856 is based on the scientifically proven immunomodulatory mode of action of sCD83, which has been investigated for close to 25 years by Mallia Co‑founder Prof. Dr Alexander Steinkasserer.⁶

Mallia Aesthetics GmbH focuses on cosmetic applications for the stimulation of hair growth, which are also based on the scientifically validated sCD83 protein. The Company develops Innovative cosmetic products using MAL-838 that are marketed to specialists and consumers.

To purchase products from the 8T3 Essentials line, please visit our online shop: www.8T3.com

For more information, visit www.mallia.com and follow us on LinkedIn, Instagram, and Facebook.
 

¹ Royzman, D., Peckert-Maier, K., Stich, L., König, C., Wild, A. B., Tauchi, M., … & Steinkasserer, A. (2022). Soluble CD83 improves and accelerates wound healing by the induction of pro-resolving macrophages. Frontiers in Immunology, 13, 1012647. DOI: 10.3389/fimmu.2022.1012647

² Bock, F., Rössner, S., Onderka, J., Lechmann, M., Pallotta, M. T., Fallarino, F., … & Zinser, E. (2013). Topical application of soluble CD83 induces IDO-mediated immune modulation, increases Foxp3+ T cells, and prolongs allogeneic corneal graft survival. The Journal of Immunology, 191(4), 1965-1975. DOI: 10.4049/jimmunol.1201531

³ Ali, N., Zirak, B., Rodriguez, R. S., Pauli, M. L., Truong, H. A., Lai, K., … & Rosenblum, M. D. (2017). Regulatory T cells in skin facilitate epithelial stem cell differentiation. Cell, 169(6), 1119-1129. DOI: 10.1016/j.cell.2017.05.002

⁴ Feinstein, R. P. (2022). Androgenetic alopecia.: https://emedicine.medscape.com/article/1070167-overview

⁵ Mostaghimi, A., Gandhi, K., Done, N., Ray, M., Gao, W., Carley, C., … & Sikirica, V. (2022). All-cause health care resource utilization and costs among adults with alopecia areata: A retrospective claims database study in the United States. Journal of Managed Care & Specialty Pharmacy, 28(4), 426-434: DOI: 10.18553/jmcp.2022.28.4.426

⁶ Lechmann, M., Krooshoop, D. J., Dudziak, D., Kremmer, E., Kuhnt, C., Figdor, C. G., … & Steinkasserer, A. (2001). The extracellular domain of CD83 inhibits dendritic cell–mediated T cell stimulation and binds to a ligand on dendritic cells. The Journal of experimental medicine, 194(12), 1813-1821. DOI: 10.1084/jem.194.12.1813

Not for release, publication or distribution, directly or indirectly, in or intothe United States of America, Australia, Canada or Japan or any otherjurisdiction in which such release, publication or distribution would be unlawful. The important notes at the end of this announcement need to be observed.

• Consistent implementation of Cantourage’s European growth strategy
• Positioning as a premium partner in Poland’s medical cannabis market
• Additional products for the Polish market currently in the registration process

Berlin, 4 November 2025 – Cantourage Group SE continues to expand its activities in the European medical cannabis market and is launching the “Gelato 33” strain from Canadian cultivator LOT420 in Poland for the first time. Following the successful introduction of the strain MAC 1 at the end of 2024, Cantourage’s collaboration with Polish wholesaler PharmaVitae continues to expand.

The Polish market experienced a temporary slowdown at the end of 2024 following regulatory changes – particularly restrictions on online prescriptions. However, market observers expect demand to recover significantly over the course of 2025 and reach new record levels in 2026.

Together with PharmaVitae, Cantourage is preparing for this anticipated growth. The two partners aim to at least double sales next year – from around 500 kilograms in 2025 to over one tonne of cannabis flowers in 2026. In addition to the now available Gelato 33 and MAC 1 varieties, four other products that are already in high demand in Germany are currently undergoing the approval process for the Polish market.

“Poland is increasingly becoming one of the most exciting European markets,” says Philip Schetter, CEO of Cantourage. “Together with PharmaVitae, we are building on an extremely successful first year. The strong demand shows that our commitment to quality resonates internationally.”

Malgożata Leman-Borsuk, CEO of PharmaVitae, adds: “Our partnership with Cantourage has proven to be extraordinarily successful from the start. With Gelato 33, we are expanding our portfolio with another strain that has great potential in Poland.”

The Canadian cultivator LOT420 is also pleased to see its products becoming available in yet another country: “At LOT420 we strive to provide patients with the best quality cannabis, being able to expand our products into a new country is always a great honor. We hope that our Gelato 33 cultivar will be well received by Poland’s medical patients and become a staple within the medical cannabis community,” says Stefan Macdonald, CEO of LOT420.

In light of the ongoing discussion about potential regulatory changes in its home market Germany, Cantourage is increasingly focusing on diversifying across Europe. At the same time, the company remains confident that Germany will continue to be its most important market. The current market developments in Poland, in particular, demonstrate that demand for high-quality and safe medical cannabis products continues to grow – regardless of the distribution channel.

About Cantourage
Cantourage is a leading European producer and distributor of cannabis flowers and cannabis-based medicinal preparations and drugs. The Berlin-based company was founded in 2019 by industry pioneers Norman Ruchholtz, Dr. Florian Holzapfel and Patrick Hoffmann. With an experienced management team and its “Fast Track Access” platform, Cantourage enables producers from around the world to become part of the growing European medical cannabis market faster, easier and more cost-effectively by processing and distributing their cannabis raw materials and extracts. In this context, Cantourage ensures compliance with the highest European pharmaceutical quality standards at all times. The company offers pharmaceutical-grade products in all relevant market segments: dried flower, extracts, dronabinol and cannabidiol. Cantourage was listed on the Frankfurt Stock Exchange on 11 November 2022 – ISIN: DE000A3DSV01.

Further information: www.cantourage.com

About PharmaVitae
PharmaVitae is a privately owner Polish company founded in 2011 that specializes in the import and distribution of Rx and OTC pharmaceuticals, medical devices and cosmetics. The company supplies pharmacies, doctors, hospitals, clinics and drugstores throughout Poland and reported annual salesof PLN 80 million in 2023. PharmaVitae ensures efficient and reliable distribution with its modern, WDL-certified warehouse that meets all GDP requirements and can accommodate up to 2,000 pallets.

Further information: www.pharmavitae.com.pl

Investor Relations contact at Cantourage

Manuel Taverne
taverne@cantourage.com

This announcement does not constitute a public offer or an advertisement for a public offer to sell securities, in particular not within the meaning of Regulation (EU) 2017/1129 (Prospectus Regulation).

Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Moderate-to-Severely Active Ulcerative Colitis

• Improvements across all patient reported outcomes (PROs) were observed from baseline to Week 8 in all PRO instruments utilized in the ABTECT induction trials evaluating bowel urgency, sleep interruption, fatigue, quality of life, and work productivity for both 50mg and 25mg once-daily obefazimod. 
• At week 8 in the ABTECT 1 & 2 trials, 37% of patients taking once daily 50mg obefazimod reported no bowel urgency (BU) compared to 18.1% of patients in the placebo group (18.9, p<0.0001[1]), with improvements in BU observed as early as week two
• 47.6% of patients on 50mg obefazimod reported no nocturnal bowel movements (NBM) at week 8 compared to 24.7% in the placebo group (23.1, p<0.0001¹)
• In the 50 mg group 17.1% of patients reported fatigue remission as measured with the Fatigue Numerical Rating Scale (NRS) at week 8, compared to 7.7% in the placebo group ( 9.5, p=0.0001¹)
• Detailed data across PROs, including data for both 25mg and 50mg groups, to be submitted for presentation at upcoming medical meetings

PARIS, France – November 3, 2025 – 10:05 PM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced patient-reported outcomes (PRO) from its Phase 3 ABTECT 8-week induction trials evaluating obefazimod in adult patients with moderate-to-severely active ulcerative colitis (UC). In addition to the trials’ clinical efficacy endpoints, PRO instruments are important in determining how patients perceived changes in their symptoms, quality of life, and activities of daily living.

“Ulcerative colitis can be a devastating condition that affects every aspect of a person’s daily life, including their ability to work, socialize, and maintain their emotional well-being,” said Marla Dubinsky, MD[2], Professor of Pediatrics and Medicine, Chief, Division of Pediatric Gastroenterology and Nutrition, Co-Director, Susan and Leonard Feinstein IBD Clinical Center, Mount Sinai Kravis Children’s Hospital, Icahn School of Medicine Mount Sinai New York. “For these patients, improvement isn’t just about controlling inflammation, it’s about regaining a sense of normalcy. That’s why measures of quality of life are so important when evaluating potential new therapies so that we also capture the outcomes that truly matter to patients, and bowel urgency is one of these key factors. The consistency of improvements across all PRO instruments utilized in this program underscores the meaningful benefit obefazimod provided to patients’ daily experience and supports the positive Phase 3 efficacy results observed at week 8. Together, these results highlight obefazimod’s potential to meaningfully advance care for patients with UC.”

PRO instruments evaluated in the ABTECT trials include:

• Bowel urgency
• Nocturnal bowel movement
• Fatigue numerical rating scale (NRS)
• Fatigue and ability to function (FACIT-F)
• Inflammatory bowel disease questionnaire (IBDQ)
• Overall quality of life (EQ-5D-5L)
• Workplace productivity (WPAI Domains)

Detailed analysis of these PROs will be submitted for presentation at an upcoming medical conference. 

Marc de Garidel, MBA, Chief Executive Officer of Abivax, commented, “The data shared today further support obefazimod’s potential as a meaningful treatment option for patients with ulcerative colitis (UC). Our development efforts, guided by the recognized need for more effective and tolerable long-term therapies, are focused on advancing treatments that can significantly improve patients’ quality of life. Taken together with the previously reported positive ABTECT 8-week induction trial results, we are one step closer to realizing this goal. We will be submitting more detailed aspects of this dataset for presentation at an upcoming medical meeting and look forward to sharing results from our 44-week maintenance trial in the second quarter of 2026.”

About Abivax

Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.

Contact:

Patrick Malloy
SVP, Investor Relations
Abivax SA
patrick.malloy@abivax.com
+1 847 987 4878

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements, forecasts and estimates, including those relating to the Company’s business. Words such as “anticipate,” “expect,” “potential” and variations of such words and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements concerning the Company’s anticipated timing for data readouts of its ABTECT induction and maintenance clinical trials and the potential therapeutic benefit of obefazimod. Although Abivax’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks, contingencies and uncertainties, many of which are difficult to predict and generally beyond the control of Abivax, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. A description of these risks, contingencies and uncertainties can be found in the documents filed by the Company with the French Autorité des Marchés Financiers pursuant to its legal obligations including its universal registration document (Document d’Enregistrement Universel) and in its Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission on March 24, 2025 under the caption “Risk Factors.” These risks, contingencies and uncertainties include, among other things, the uncertainties inherent in research and development, future clinical data and analysis, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug candidate, as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, and the availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements. Special consideration should be given to the potential hurdles of clinical and pharmaceutical development, including further assessment by the Company and regulatory agencies and IRBs/ethics committees following the assessment of preclinical, pharmacokinetic, carcinogenicity, toxicity, CMC and clinical data. Furthermore, these forward-looking statements, forecasts and estimates are made only as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Abivax disclaims any obligation to update these forward-looking statements, forecasts or estimates to reflect any subsequent changes that the Company becomes aware of, except as required by law. Information about pharmaceutical products (including products currently in development) that is included in this press release is not intended to constitute an advertisement. This press release is for information purposes only, and the information contained herein does not constitute either an offer to sell or the solicitation of an offer to purchase or subscribe for securities of the Company in any jurisdiction. Similarly, it does not give and should not be treated as giving investment advice. It has no connection with the investment objectives, financial situation or specific needs of any recipient. It should not be regarded by recipients as a substitute for exercise of their own judgment. All opinions expressed herein are subject to change without notice. The distribution of this document may be restricted by law in certain jurisdictions. Persons into whose possession this document comes are required to inform themselves about and to observe any such restrictions.  

[1] ABTECT-1&2 pooled analysis; all p-values are nominal.  Endpoints are secondary and not alpha controlled.

[2] Marla Dubinsky, MD is a paid consultant for Abivax.

Press release 

Thomas Meier becomes new CEO of Medios AG

Berlin, November 3, 2025 – The Supervisory Board of Medios AG has appointed Thomas Meier as a member of the Executive Board with effect from February 1, 2026, and designated him the new Chief Executive Officer (CEO) of the Company. He succeeds Matthias Gaertner, who will remain in office until December 31, 2025.

Thomas Meier has been CEO of the Swiss CDMO (Contract Development and Manufacturing Organization) company Bachem Holding AG, which is also listed on the stock exchange, since 2020. Prior to this, he was Chief Operations Officer on the Executive Board of Bachem and worked as Head of Manufacturing at Peninsula Laboratories in San Carlos, California, USA, from 2001 to 2004. Thomas Meier will play a key role in driving the further growth of the Medios Group.

Dr. Yann Samson, Chairman of the Supervisory Board of Medios AG: “With Thomas Meier, we are gaining an internationally experienced leader with a strong track record of capital-efficient, profitable growth. We warmly welcome him and are convinced that his entrepreneurial spirit, expertise and leadership will contribute significantly to achieving our ambitious goals and sustainably increasing value for shareholders, partners, and customers. At the same time, on behalf of the entire Supervisory Board, I would like to express my sincere thanks to Matthias Gaertner for his outstanding work and great commitment over the past ten years. He has had a decisive influence on the growth and success of Medios.”

Thomas Meier: “I am very much looking forward to the task of leading Medios into its next phase of development. Together with my colleagues on the Executive Board and the entire Medios team, I will continue to consistently develop the successful strategy and sustainably expand Medios’ position in the European Specialty Pharma market.”
 

Important dates for Medios in the 2025 financial year

——————-

About Medios AG

Medios is a leading provider of Specialty Pharma in Europe. With locations in Germany, the Netherlands, Belgium and Spain, the Company supports key partners in the supply chain with innovative solutions and intelligent services. Medios has focused on pioneering individualized medicine to make the most innovative therapies available to everyone together with pharmacies, specialist practices and pharmaceutical companies.

Medios AG is Germany’s first listed specialty pharmaceutical Company. The shares (ISIN: DE000A1MMCC8) are listed on the regulated market of the Frankfurt Stock Exchange (Prime Standard) and are included in the SDAX selection index.

www.medios.group 

More information on the topic of individualized medicine: https://app.medios.group/en/individualizedmedicine
 

Contact

Claudia Nickolaus

Head of Investor & Public Relations, ESG Communications

Medios AG

Heidestraße 9 | 10557 Berlin

T +49 30 232 566 800

ir@medios.group

www.medios.group